A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130225121601im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
COL-3 may stop the growth of cancer by stopping blood flow to the tumor. Randomized phase II trial to compare the effectiveness of two different regimens of COL-3 in treating patients who have HIV-related Kaposi's sarcoma
Condition | Intervention | Phase |
---|---|---|
AIDS-related Kaposi Sarcoma HIV Infection |
Drug: incyclinide Other: laboratory biomarker analysis |
Phase 2 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma |
- Overall response rate [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]Binomial proportions and their 95% confidence intervals will be used to estimate the overall response rate for each treatment group.
- Response duration [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]The Kaplan-Meier Method will be used to estimate the distribution of response duration for each treatment group.
- Frequency of adverse events and their severity [ Time Frame: Up to 6 years ] [ Designated as safety issue: Yes ]Will be tabulated to evaluate tolerance of each dose level in the treatment of AIDS-related Kaposi's Sarcoma.
- Time to response [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]The Kaplan-Meier Method will be used to estimate the distribution of time to response for each treatment group.
- Quality of life [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]Individual composite scores will be constructed. Repeated measures and an analysis of variance will be performed on the composite scores to evaluate changes with time. Mixed models will be applied to the analysis of the composite score.
- Relationship between clinical response and quantitative measures of KSHV/HHV8 and HIV viral load [ Time Frame: Up to 6 years ] [ Designated as safety issue: No ]These measures will be tested to determine if they are normally distributed. If the data are non-normal, the data will be transformed for analysis purposes. The logistic regression model will be used to assess the relationship between qualification of baseline levels of KSHV/HHV-8, HIV viral load and response. The proportional hazards model will be used to evaluate the relationship between the qualification of baseline KSHV/HHV8 and HIV viral load and time to progression, and response duration.
Enrollment: | 70 |
Study Start Date: | March 2003 |
Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: Arm I (low dose incyclinide)
Patients receive low-dose oral COL-3 once daily. Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed. |
Drug: incyclinide
Low dose given orally
Other Names:
Other: laboratory biomarker analysis
Correlative studies
|
Experimental: Arm II (high dose incyclinide)
Patients receive high-dose oral COL-3 once daily. Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed. |
Drug: incyclinide
High dose given orally
Other Names:
Other: laboratory biomarker analysis
Correlative studies
|
Detailed Description:
PRIMARY OBJECTIVES:
I. To evaluate the tumor response rate and response duration of treatment with Col-3 at two different dose levels- 50 mg/day and 100 mg/day in subjects with HIV related KS.
II. To evaluate the biologic activity of Col-3 by measuring percent apoptotic cells on tumor biopsies pre- and post-treatment.
III. To evaluate the effect of Col-3 on serum levels of MMP-2 and MMP-9.
SECONDARY OBJECTIVES:
I. To determine the safety and toxicity of Col-3 at two different dose levels in HIV related KS.
II. To evaluate the effect of Col-3 on overall quality of life. III. To evaluate the relationship between clinical response and quantitative measures of KSHV/HHV-8 and HIV viral load.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive low-dose oral COL-3 once daily.
Arm II: Patients receive high-dose oral COL-3 once daily.
Treatment on both arms continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed.
Patients are followed for at least 1 month.
PROJECTED ACCRUAL: A total of 70 patients (35 per treatment arm) will be accrued for this study within 1.75 years.
![](https://webarchive.library.unt.edu/web/20130225121601im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Biopsy proven KS involving the skin , lymph nodes, oral cavity, gastrointestinal (GI) tract and/or lungs; GI and pulmonary involvement must be asymptomatic or minimally symptomatic and not require systemic cytotoxic therapy; at least five measurable, previously non-radiated, cutaneous lesions must be present which can be used as indicator lesions
- Serologic documentation of HIV infection at any time prior to study entry, as evidenced by positive ELISA, positive Western Blot, or other federally approved licensed HIV test
- Karnofsky performance status >= 60%
- Hemoglobin >= 8.0 gm/dl
- Absolute neutrophil count >= 750 cells/mm^3
- Platelet count >= 75,000/mm^3
- Serum creatinine =< 1.5 mg/dl or a measured creatinine clearance of > 60 ml/min
- Total bilirubin should be normal; if, however, the elevated bilirubin is felt to be secondary to indinavir therapy, then subjects will be allowed on protocol if bilirubin < 3.5 mg/dl, provided that the direct bilirubin is normal
- AST (SGOT) and ALT (SGPT) =< 2.5 times the ULN
- PT and PTT < 120% of normal
- Life expectancy of 3 months or more
- Ability and willingness to give informed consent
- All women of childbearing potential must have a negative serum beta HCG within 72 hours prior to study entry and must practice adequate birth control to prevent pregnancy while receiving study treatment and for 3 months after treatment is discontinued; all males of child fathering potential must also practice adequate birth control; pregnant or breast feeding females are excluded from participation in this study since the effects of Col-3 on an unborn or young child are unknown and may potentially be toxic
- Subjects must, in the opinion of the investigator, be capable of complying with this protocol
Exclusion Criteria:
- Concurrent active opportunistic infection (OI)
- Concurrent neoplasia requiring cytotoxic therapy
- Acute treatment for an infection or other serious medical illness within 14 days prior to study entry
- Prior anti-neoplastic treatment for KS within 3 weeks of study entry; patients must also have completely recovered from any associated toxicity
- Previous local therapy of any KS indicator lesion within 60 days, unless the lesion has progressed since treatment; because of the possibility of tattooing and the difficulty in ascertaining clinically what is active KS versus residual pigment post treatment, any prior local treatment to the indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesion
- Anti-retroviral therapy is permitted but not required; if patients are taking anti-retroviral therapy, their regimen must not have changed within 4 weeks of starting the study medication; patient should be receiving an optimal and stable regimen of HAART for a minimum of 4 weeks prior to entry
- Subjects must not have received blood products within 4 weeks of study entry and must not have received granulocyte colony stimulating factor or erythropoietin within 2 weeks of study entry
- Evidence of a prior MI or cardiac ischemia
![](https://webarchive.library.unt.edu/web/20130225121601im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
United States, Maryland | |
AIDS - Associated Malignancies Clinical Trials Consortium | |
Rockville, Maryland, United States, 20850 |
Principal Investigator: | Bruce Dezube | AIDS Associated Malignancies Clinical Trials Consortium |
![](https://webarchive.library.unt.edu/web/20130225121601im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00020683 History of Changes |
Other Study ID Numbers: | NCI-2012-02924, AMC-027, U01CA070019, CDR0000068703 |
Study First Received: | July 11, 2001 |
Last Updated: | January 4, 2013 |
Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Sarcoma, Kaposi AIDS-Related Opportunistic Infections Sarcoma Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes |
Immune System Diseases Slow Virus Diseases Herpesviridae Infections DNA Virus Infections Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Neoplasms, Vascular Tissue Opportunistic Infections Infection Parasitic Diseases |
ClinicalTrials.gov processed this record on February 21, 2013